Ironwood Investor Relations Alert: Q4 2024 Earnings Call Scheduled for February 27

2025-12-31 10:13:17

Biotech company Ironwood Pharmaceuticals (Nasdaq: IRWD) has confirmed it will hold its fourth quarter and full year 2024 financial briefing via conference call and webcast on Thursday, February 27, 2025, at 8:30 a.m. ET.

How to Access the Earnings Update

Interested parties can dial into the live session using:

U.S./Canada: (888) 596-4144
International: (646) 968-2525
Conference ID and passcode: 2530602

For those preferring the webcast format, the virtual session will be streamed through the Investors section of Ironwood’s official website at www.ironwoodpharma.com.

Replay Details

Missing the live call? A telephone replay launches Thursday, February 27, 2025, at approximately 11:30 a.m. ET and remains available through 11:59 p.m. ET on Thursday, March 13, 2025.

Replay dial-in numbers:

U.S./Canada: (800) 770-2030
International: (609) 800-9909
Conference ID: 2530602

The archived webcast will remain accessible on Ironwood’s investor relations page for one year following the call conclusion.

Why This Matters for Biotech Investors

Ironwood Pharmaceuticals, headquartered in Boston, Massachusetts, stands out as a key player in gastrointestinal and rare disease therapeutics. The company’s portfolio includes:

LINZESS (linaclotide) – The leading U.S. branded prescription therapy for adults suffering from irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). The drug also holds FDA approval for treating functional constipation in pediatric patients aged 6-17 years.

Apraglutide – An innovative, long-acting synthetic GLP-2 analog currently in development for short bowel syndrome patients requiring parenteral support. This next-generation candidate represents significant potential for addressing an unmet clinical need.

Established in 1998, the company maintains operational sites in Boston and Basel, Switzerland, reflecting its commitment to innovation in patient care across gastrointestinal and rare disease spaces.

For the latest investor relations updates, follow Ironwood on X and LinkedIn, or visit www.ironwoodpharma.com regularly.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.